secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001396814-25-000017
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan
--------------------------------------------------------------------------------

- Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.
- Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.
- Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.
- Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.
- Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/pcrx-20250116.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer